Century Therapeutics/$IPSC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Century Therapeutics
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
- Ticker
- $IPSC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 78
- Headquarters
- Philadelphia, United States
- Website
- www.centurytx.com
IPSC Metrics
BasicAdvanced
$273M
-
-$0.77
1.60
-
Price and volume
Market cap
$273M
Beta
1.6
52-week high
$3.04
52-week low
$0.44
Average daily volume
923K
Financial strength
Current ratio
8.28
Quick ratio
8.043
Long term debt to equity
0.149
Total debt to equity
0.166
Profitability
EBITDA (TTM)
-95.223
Effective tax rate (TTM)
0.06%
Management effectiveness
Return on assets (TTM)
-23.51%
Return on equity (TTM)
-49.65%
Valuation
Price to book
1.17
Price to tangible book (TTM)
1.38
Price to free cash flow (TTM)
-2.457
Free cash flow yield (TTM)
-40.70%
Free cash flow per share (TTM)
-0.615
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
180.28%
3-year earnings per share growth (CAGR)
-29.32%
What the Analysts think about IPSC
Analyst ratings (Buy, Hold, Sell) for Century Therapeutics stock.
Analyst projections of the future price of Century Therapeutics stock.
IPSC Financial Performance
Revenues and expenses
IPSC Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing IPSC
Fund name | Fund size | $IPSC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.